Article

G72/G30 in Schizophrenia and Bipolar Disorder: Review and Meta-analysis

National Institute of Mental Health Intramural Research Program, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, Maryland 20892-3719, USA.
Biological Psychiatry (Impact Factor: 10.25). 08/2006; 60(2):106-14. DOI: 10.1016/j.biopsych.2006.01.019
Source: PubMed

ABSTRACT Association of the G72/G30 locus with schizophrenia and bipolar disorder has now been reported in several studies. The G72/G30 locus may be one of several that account for the evidence of linkage that spans a broad region of chromosome 13q. However, the story of G72/G30 is complex. Our meta-analysis of published association studies shows highly significant evidence of association between nucleotide variations in the G72/G30 region and schizophrenia, along with compelling evidence of association with bipolar disorder. But the associated alleles and haplotypes are not identical across studies, and some strongly associated variants are located approximately 50 kb telomeric of G72. Interestingly, G72 and G30 are transcribed in opposite directions; hence, their transcripts could cross-regulate translation. A functional native protein and functional motifs for G72 or G30 remain to be demonstrated. The interaction of G72 with d-amino acid oxidase, itself of interest as a modulator of N-methyl-d-aspartate receptors through regulation of d-serine levels, has been reported in one study and could be a key functional link that deserves further investigation. The association findings in the G72/G30 region, among the most compelling in psychiatry, may expose an important molecular pathway involved in susceptibility to schizophrenia and bipolar disorder.

Download full-text

Full-text

Available from: Francis J Mcmahon, Jul 31, 2015
0 Followers
 · 
106 Views
  • Source
    • "Nevertheless, lithium has been used for over 35 years for the treatment of BD, being the gold standard and perhaps the most widely used drug. Various theories on the mechanism of lithium action have been proposed, from alterations in ionic transport to modulation of gene expression [6] [7]. However, the precise neurobiological mechanisms through which lithium exerts its clinical effects are not clear, and some results found in the literature are contradictory [2]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The molecular basis of bipolar disorder (BD) is still unknown as is the mechanism through which lithium, the therapy of choice, exerts its effects in treatment of BD. So far, no biomarkers exist to facilitate diagnosis of BD or treatment evaluation. To investigate whether BD and its treatment with lithium leaves a characteristic signature in the serum proteome, we used SELDI-TOF MS to analyze individual serum samples from BD patients treated with lithium (BD-plus-Li, n=15) or other drugs (BD-minus-Li, n=10) and from healthy controls (n=15). Interestingly, features of 28 kDa (one peak) and 14 kDa (three peaks) showed a decreased level in the BD-minus-Li group and a level restored to that of the control group in the BD-plus-Li group. To reveal the identity of these features, we subjected pooled serum samples from both BD groups to the 2-D DIGE technology and identified 28 kDa apolipoprotein A-I (apo A-I) and three 14 kDa fragments thereof as upregulated in the BD-plus-Li group. Immunoturbidimetry, a routine clinical assay, verified the characteristic apo A-I signature in individual serum samples. In conclusion, we propose apo A-I as a candidate marker that can visualize response to lithium treatment at the serum protein level.
    Proteomics 01/2011; 11(2):261-9. DOI:10.1002/pmic.201000371 · 3.97 Impact Factor
  • Source
    • "In this perspective, G72 deserved priority as candidate gene, given the evidence provided in literature. After its identification as genetic risk factor in schizophrenia [7], the association with G72 was positively replicated in independent cohorts of patients affected with schizophrenia, bipolar disorder, and other mental illnesses [19]. The statistical evidence of genetic association was supported by the biological function exerted by the DAOA gene, coded in the G72 locus. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The occurrence of neuropsychiatric symptoms in patients with Alzheimer's disease hampers the clinical management and exacerbates the burden for caregivers. To what extent psychotic symptoms are genetically determined and which are the genes involved has to be established. We tested the hypothesis that the occurrence of delusions and hallucinations in AD is associated with variations in the G72/DAOA gene, which is supposed to play a key role in the glutamate pathway regulated through the NMDA receptors. A panel of single nucleotide polymorphisms were genotyped in a cohort of 185 Alzheimer's disease patients. The analysis demonstrated a nominally significant association (p< 0.05) with one single nucleotide polymorphism (rs2153674). In addition, multivariate regression showed that the rs2153674 genotype accounts for up to 15% of the variance in delusions severity, as assessed by using the Neuropsychiatric Inventory. If the results from the present study will be replicated, the glutamate hypothesis could be invoked to explain the occurrence of psychosis in neurodegenerative disorders.
    Journal of Alzheimer's disease: JAD 01/2009; 18(4):953-60. DOI:10.3233/JAD-2009-1194 · 4.15 Impact Factor
  • Source
    • "With the hypothesis, therefore, that genetic factors modulate longitudinal brain changes, we investigated the role of a high interest gene, G72, in producing these changes. Variation in G72 has been associated with schizophrenia in multiple samples (Abecasis et al., 2004; Addington et al., 2004; Chen et al., 2004; Detera-Wadleigh and McMahon 2006; Fallin et al., 2005; Korostishevsky et al., 2004; Li and He 2007; Ma et al., 2006; Schulze et al., 2005; Shi et al., 2008; Wang et al., 2004; Wood et al., 2006; Yue et al., 2006; Zou et al., 2005). G72 has been shown to influence, in individuals with schizophrenia, symptom severity (Schulze et al., 2005; Yue et al., 2007) and cognitive processes that depend on frontal lobe function (Donohoe et al., 2007; Goldberg et al., 2006) . "
    [Show abstract] [Hide abstract]
    ABSTRACT: Schizophrenia is a neurodevelopmental psychiatric disorder characterized by a variety of structural brain abnormalities that appear to progress across the course of illness. Schizophrenia also is highly heritable, and one gene that has emerged as a possible susceptibility factor is G72. G72 influences brain development and activity by an as-yet unclear mechanism, and multiple studies have reported associations between G72 and schizophrenia. We were interested in linking these domains of investigation by determining whether G72 also influences the rate of longitudinal structural brain changes in individuals with schizophrenia. As part of the Iowa Longitudinal Study of Recent Onset Psychoses, we genotyped four G72 polymorphisms previously associated with schizophrenia in 110 subjects with schizophrenia or schizoaffective disorder from whom we had obtained two brain MRI scans an average of 3 years apart. The four polymorphisms captured three haplotypes, one of which was strongly associated with an increased rate of frontal lobe volume decrement. This same haplotype was also associated with more severe psychotic symptoms at the time of the second scan. These data thus suggest that variation in G72 modulates the progressive brain changes that characterize schizophrenia.
    American Journal of Medical Genetics Part B Neuropsychiatric Genetics 01/2009; 153B(2):640-7. DOI:10.1002/ajmg.b.31033 · 3.27 Impact Factor
Show more